Supriya Lifescience Q2 FY27: revenue up 3.3% to ₹206 Cr, net profit down 42.1% to ₹29 Cr
Results · Finvezto · 6 Nov 2026 · Supriya Lifescience (SUPRIYA)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 206 | +8.7% | +3.3% |
| Operating profit | 45 | -4.4% | -37.5% |
| Net profit | 29 | +21.7% | -42.1% |
| Operating margin | 22.0% | -3.0 pp | -14.4 pp |
| Net margin | 14.2% | +1.5 pp | -11.1 pp |
Key points
- For Q2 FY27, Supriya Lifescience Limited reported consolidated revenue of Rs 206.30 crore, up 3.2% from Rs 199.83 crore in Q2 FY26, with EBITDA decreasing to Rs 45.40 crore from Rs 72.65 crore and PAT falling to Rs 29.25 crore from Rs 50.43 crore. NSE filing
- Margins were impacted by regulatory changes in the LATAM market, ramp-up costs at the Ambernath facility, and elevated raw material and solvent prices. NSE filing
- Revenue was ₹206 Cr, up 3.3% on a year earlier and up 8.7% on the quarter before. Finvezto data
Other figures
- Consolidated Revenues: ₹206 Cr (+3.2% YoY)
What to watch
- Operating margin over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26): 34.9%, 35.3%, 25.0%, 22.0%.
- Net profit over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26), ₹ Cr: 50, 74, 24, 29.
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.